Viva Biotech Establishes RMB 300M Fund for Early-Stage Pharma Projects
China-based Contract Research Organization (CRO) Viva Biotech (HKG: 1873) announced that its wholly-owned subsidiary, Hangzhou...
HKG: 1873
VIVA Biotech Expands Global Footprint with New Boston Branch
China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its...
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases,...
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...
Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program
US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva...
Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a...
VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a...